CTXR

Citius Pharmaceuticals Inc

0.5446

Nov 05 • 11:56 AM ET -0.0064 (-1.16%)

Healthcare Biotechnology USA Nano NASD

Nov 04, 1:50 PMCitius Oncology reports Study 302 data showing sustained quality-of-life benefits for LYMPHIR in relapsed or refractory CTCL

Peers: SNGX CRMD KPTI FBIO CHRS ATNM PYPD SPRO MAIA TNXP

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	14.95M
Enterprise Value	14.42M
Income	-46.27M
Sales	7.11M
Book/sh	2.43
Cash/sh	0.62
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	23
IPO	Oct 02, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	2.10
P/B	0.22
P/C	0.88
P/FCF	-
EV/EBITDA	-
EV/Sales	2.03
Quick Ratio	0.40
Current Ratio	0.84
Debt/Eq	0.11
LT Debt/Eq	0.11
Option/Short	Yes / No

EPS (ttm)	-2.11
EPS next Y	-1.44
EPS next Q	-0.41
EPS this Y	39.94%
EPS next Y	29.06%
EPS next 5Y	41.69%
EPS past 3/5Y	16.24% 21.29%
Sales past 3/5Y	- -
EPS Y/Y TTM	57.48%
Sales Y/Y TTM	-
EPS Q/Q	57.59%
Sales Q/Q	-
Earnings	Aug 14 AMC
EPS/Sales Surpr.	5.56% -72.64%

Insider Own	1.80%
Insider Trans	0.00%
Inst Own	5.16%
Inst Trans	-2.81%
ROA	-34.29%
ROE	-70.29%
ROIC	-62.86%
Gross Margin	19.97%
Oper. Margin	-863.92%
Profit Margin	-651.27%
SMA20	12.55%
SMA50	2.19%
SMA200	-16.40%
Trades

Shs Outstand	27.45M
Shs Float	26.96M
Short Float	21.14%
Short Ratio	12.23
Short Interest	5.70M
52W High	1.54 -64.63%
52W Low	0.37 47.23%
Volatility	12.66% 10.17%
ATR (14)	0.05
RSI (14)	55.37
Beta	1.04
Rel Volume	1.30
Avg Volume	465.96K
Volume	250,213

Perf Week	-3.29%
Perf Month	8.68%
Perf Quarter	-20.18%
Perf Half Y	-16.74%
Perf YTD	-29.91%
Perf Year	-60.25%
Perf 3Y	-97.19%
Perf 5Y	-98.88%
Perf 10Y	-99.72%
Recom	1.00
Target Price	4.00
Prev Close	0.55
Price	0.54
Change %	-1.16%

Consensus

Strong Buy

Avg. Price Target

$4.00

Implied Upside

+634.5%

Analysts2incl. previous ratings

Rating Distribution2 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Dec 30, 2024	Upgrade	DD. Boral Capital	Hold → Buy	$9	+1,552.6%
Nov 30, 2021	Initiated	MMaxim Group	Buy	$4	+634.5%

Nov-04-26 01:45PM	Citius Oncology's Positive Quality of Life Data for LYMPHIR (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe (PR Newswire)
Oct-26-26 01:00PM	Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 (PR Newswire) +11.38%
Oct-12-26 08:30AM	Citius Pharmaceuticals to Participate in October 2026 Investor Conferences (PR Newswire)
Sep-03-26 08:30AM	Citius Pharmaceuticals to Participate in September 2026 Investor Conferences (PR Newswire)
Aug-14-26 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update (PR Newswire) -25.62%
04:30PM	Loading…
04:30PM	Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
Aug-12-26 08:00AM	Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri (PR Newswire) +6.25%
Aug-05-26 09:17AM	Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment (PR Newswire) +25.45%
Jul-21-26 09:17AM	Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption (PR Newswire) +13.50%
Jun-01-26 07:00AM	Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies (PR Newswire)
May-26-26 08:00AM	Citius Oncology Announces Presentation of LYMPHIR Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting (PR Newswire)
May-15-26 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire) -24.76%
04:30PM	Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
Apr-29-26 08:00AM	Citius Oncology Ships First International Order of LYMPHIR to Europe (PR Newswire) -8.46%
Apr-24-26 04:30PM	Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire) -17.47% -10.26%
10:48AM	Loading…
10:48AM	Citius Pharmaceuticals Secures $5M Through Equity Offering (InvestorsHub)
08:00AM	Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Mar-31-26 09:11AM	Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development (PR Newswire) +32.28%
Mar-24-26 08:00AM	Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts (PR Newswire) -5.48%
Mar-10-26 08:47AM	Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers (PR Newswire) +10.97%
Mar-06-26 03:00PM	Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR (Insider Monkey) -11.97%
Feb-24-26 08:00AM	Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program (PR Newswire) +12.65%
Feb-13-26 08:00AM	Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR (PR Newswire)
08:00AM	Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR (PR Newswire)
Feb-12-26 06:55AM	Citius Oncology and Uniphar sign European distribution deal for Lymphir (Pharmaceutical Technology) -11.78%
Feb-11-26 08:00AM	Citius Oncology Expands International Distribution of LYMPHIR to European Union Through Exclusive Agreement with Uniphar (PR Newswire) +10.82%
Dec-23-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update (PR Newswire) -23.02%
04:30PM	Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update (PR Newswire)
Dec-09-25 08:30AM	Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) +7.14%
Dec-04-25 08:37AM	Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim (PR Newswire) +9.17%
12:00PM	Loading…
Dec-01-25 12:00PM	Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) (PR Newswire) -6.25%
Nov-21-25 08:37AM	Citius Oncology to Advance Commercial Launch of LYMPHIR with Verix AI Integration (PR Newswire) +15.15%
Oct-21-25 04:30PM	Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire) -7.18% -6.55%
08:00AM	Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Oct-20-25 08:37AM	Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR Commercial Launch (PR Newswire) +24.83%
Oct-17-25 05:00PM	Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences (PR Newswire)
Oct-16-25 08:47AM	Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR (PR Newswire) +6.47%
Sep-10-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Sep-09-25 08:30AM	Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Aug-22-25 08:47AM	Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch (PR Newswire) +9.76%
Aug-12-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
04:30PM	Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Jul-17-25 04:30PM	Citius Oncology Announces Closing of $9.0 Million Public Offering (PR Newswire) +7.05%
Jul-16-25 09:15AM	Citius Oncology Announces Pricing of $9.0 Million Public Offering (PR Newswire) -8.59%
Jul-15-25 08:32AM	Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora (PR Newswire)
Jul-08-25 08:34AM	Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (PR Newswire) -8.08%
Jul-06-25 04:01AM	Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR (Insider Monkey)
Jun-17-25 08:08AM	Citius Oncology Anticipates Commercial Launch of LYMPHIR in 2025 (PR Newswire) +8.00%
Jun-12-25 09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire) -8.91%
08:35AM	Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Jun-10-25 07:00AM	Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire) -22.63%
Jun-09-25 08:37AM	Citius Oncology Enters into Distribution Services Agreement with Cardinal Health (PR Newswire) +60.99%
May-14-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire) +19.20% -11.74%
May-05-25 08:37AM	Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (PR Newswire) +5.33%
Apr-01-25 09:00AM	Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock (PR Newswire) -19.46%
Feb-14-25 04:30PM	Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update (PR Newswire) -8.18%
Feb-06-25 08:55AM	Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services (PR Newswire)
Jan-08-25 08:00AM	Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (PR Newswire) -15.10%
Jan-07-25 08:08AM	Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 (PR Newswire) +11.76%
07:57AM	Citius Oncology to explore strategic alternatives (TipRanks)
Jan-06-25 07:50AM	Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives (PR Newswire)
Dec-31-24 07:10AM	Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital (TipRanks)
Dec-30-24 09:43AM	American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls (The Fly) +6.25%
Dec-29-24 10:50PM	Citius Pharma Reports 2024 Financial Results and Business Update (TipRanks)
Dec-27-24 05:00PM	Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update (PR Newswire) +11.18% +6.25%
Nov-25-24 08:03AM	Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok Program and Pathway to Approval (PR Newswire)
Nov-22-24 09:00AM	Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split (PR Newswire) -18.96%
Nov-18-24 04:05PM	Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering (PR Newswire) +12.10% -14.45%
Nov-15-24 01:30PM	Citius Pharmaceuticals Announces $3 Million Registered Direct Offering (PR Newswire) -39.10%
Nov-11-24 08:45AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients with Recurrent Solid Tumors (PR Newswire) +9.16%
Sep-05-24 04:30PM	Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
08:30AM	Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (PR Newswire)
Aug-13-24 09:30AM	Sidoti Events, LLC's Virtual August Micro-Cap Conference (ACCESSWIRE) -11.69%
04:32AM	Citius merges oncology subsidiary with TenX Keane (Pharmaceutical Technology)
Aug-12-24 10:53PM	CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024 (InvestorPlace) -11.38%
05:28PM	Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
04:22PM	Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. (PR Newswire)
08:00AM	Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments (PR Newswire)
Aug-09-24 07:30AM	TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update (GlobeNewswire) -12.36%
Aug-08-24 05:41PM	Penny Stock Citius Pharmaceuticals Secures Its First FDA Approval For Skin Cancer Drug A Year After FDA Rejection (Benzinga)
06:59AM	Citius Pharmaceuticals Receives FDA Approval for LYMPHIR (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma (PR Newswire)
Aug-05-24 08:00AM	TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals (GlobeNewswire)
08:00AM	Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. (PR Newswire)
Jul-18-24 07:00AM	Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL) (Newsfile)
Jul-17-24 08:00AM	Analysts Hunt for Undervalued Biotech Stocks (Newsfile)
Jul-11-24 11:00AM	Bloodstream Infections - From Threats to Solutions (Newsfile)
08:00AM	Biopharma Stocks Transformative Innovation for the Future of Health (Newsfile)
Jul-10-24 09:10AM	Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates (PR Newswire) +10.29%
Jul-07-24 09:01AM	2 Biotech Stocks With Big FDA Decisions Approaching Heres What Analysts Expect (TipRanks)
Jun-11-24 10:50AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
May-29-24 08:30AM	Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution (PR Newswire)
May-21-24 11:42AM	Yogi Tea Recalls: Yogi Brand Recalls 900,000 Tea Bags for Pesticide Residue (InvestorPlace) +10.64%
11:20AM	VFS Stock Alert: VinFast Plunges on NHTSA Probe (InvestorPlace)
10:58AM	Why Is Citius Pharmaceuticals (CTXR) Stock Up 11% Today? (InvestorPlace)
07:00AM	Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution (PR Newswire)
May-14-24 10:55PM	CTXR Stock Earnings: Citius Pharma Meets EPS for Q2 2024 (InvestorPlace) -9.15%
04:05PM	Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-10-24 08:30AM	Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences (PR Newswire)
Apr-30-24 04:05PM	Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering (PR Newswire) +7.85%
Apr-26-24 10:43AM	Citius Pharmaceuticals Launches $15 Million Offering (MT Newswires) -9.25%

Show Previous News

Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone, Leonard Mazur, Myron Holubiak on January 23, 2007 and is headquartered in Cranford, NJ.

Co-FounderMr. Leonard L. Mazur

Co-Founder & Executive Vice ChairmanMr. Myron Z. Holubiak

Executive VP & Chief Medical OfficerDr. Myron S. Czuczman M.D.

Chief Business Officer & CFOMr. Jaime Bartushak

Executive Vice President of OperationsMr. Gary F. Talarico

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTXR

Citius Pharmaceuticals Inc

Upgrade your Finviz experience